Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

Autor: Luca Toti, Roberta Angelico, Alessandro Anselmo, Andrea del Monaco, Ilaria Lenci, Tommaso Maria Manzia, Leonardo Baiocchi, Carlo Gazia, Paolo Grossi, Giuseppe Tisone
Rok vydání: 2021
Předmět:
Adult
infection and infectious agents - viral
Waiting Lists
Coronavirus disease 2019 (COVID-19)
infectious disease
viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
medicine.medical_treatment
donors and donation: extended criteria
organ procurement and allocation
Case Report
Liver transplantation
clinical research/practice
Settore MED/12
Liver disease
infection and infectious agents ‐ viral
Case fatality rate
medicine
Humans
Immunology and Allergy
Pharmacology (medical)
Infectious disease (athletes)
skin and connective tissue diseases
Transplantation
biology
SARS-CoV-2
business.industry
fungi
COVID-19
virus diseases
medicine.disease
Tissue Donors
Liver Transplantation
Settore MED/18
body regions
liver transplantation/hepatology
Titer
Immunology
biology.protein
Female
Antibody
business
Zdroj: American Journal of Transplantation
ISSN: 1600-6135
DOI: 10.1111/ajt.16548
Popis: The coronavirus disease 2019 (COVID‐19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 currently affected more than 108 million people worldwide with a fatality rate of 2.2%. Herein, we report the first case of liver transplantation (LT) performed with a liver procured from a SARS‐CoV‐2 positive donor. The recipient was a 35‐year‐old SARS‐CoV‐2 positive female patient affected by severe end‐stage HBV‐HDV‐related liver disease (model of end‐stage liver disease = 32) who had neutralizing SARS‐CoV‐2 antibodies (titers 1:320) at time of LT. The LT was successful, and the graft is functioning two months after surgery. The recipient cleared the SARS‐CoV‐2 infection 1 month after LT. The current case shows that the prompt use of SARS‐CoV‐2 infected liver donors offers an invaluable life‐saving opportunity for SARS‐CoV‐2 positive wait‐listed patients who developed neutralizing SARS‐CoV‐2 antibodies.
Databáze: OpenAIRE
Externí odkaz: